Sentences with phrase «primary hypogonadism»

This rather common and treatable condition is broken down into two types — primary hypogonadism and secondary hypogonadism.

This article from The National Center for Biotechnology Information sums up the benefits of testosterone replacement therapy (TRT) for men suffering from all forms of low testosterone, including primary hypogonadism:

Primary hypogonadism, or testicular failure, is found to be the most common cause of low testosterone in younger men.

The following are some medical conditions that can result in testicular trauma, which then leads to primary hypogonadism:

Primary hypogonadism generally refers to a condition that is more severe, and, often, more permanent.

For younger men, especially those under 30, primary hypogonadism is the most likely cause of low testosterone, but there can also be other reasons behind the condition — click the button below to find out more about low testosterone in young men.

Those are much needed benefits for someone suffering from primary hypogonadism.

Primary hypogonadism is often referred to as primary testicular failure — your testicles are not able to produce the necessary testosterone for balanced hormone levels, often due to injury or trauma.

Many health issues can occur at birth that affect the production of testosterone and these will all fall under the category of primary hypogonadism.

The first type is called primary hypogonadism or testicular failure.

Hypogonadism (the medical term for low testosterone) falls into two main categories, primary hypogonadism and secondary hypogonadism.

We often find primary hypogonadism to be the issue when treating a younger male for low testosterone.

When we say that testicular cancer can cause low testosterone, we are referring to primary hypogonadism — failure of the testes to perform their role of testosterone production (and possibly sperm production as well).

Not exact matches

administering to the subject an effective amount of a compound that stimulates bone formation and inhibits bone resorption, wherein said compound is an agonist of a cannabinoid receptor and wherein said subject having a bone disease or condition is a subject having a disease or condition selected from the group consisting of periodontal disease or defect, osteolytic bone disease other than osteoporosis, post-plastic surgery, post-orthopedic implantation, post-dental implantation, age - related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes - related osteoporosis, osteoporosis associated with depression, osteoporosis associated with hypogonadism and glucocorticoid - related osteoporosis.

Primary testicular failure Klinefelter syndrome Cryptorchidism Orchitis Trauma HIV / AIDS Myotonic muscular deficiency Retroperitoneal fibrosis Aging Hypogonadotropic hypogonadism Kallman syndrome Prader - Willi syndrome Idiopathic hypopituitarism Pituitary tumors Suprasellar tumors Hemochromatosis Inflammatory, traumatic, vascular lesions of pituitary and hypothalamus Obesity Severe chronic illnesses Medication Andropause

The prevalence of hypogonadism (defined as a total testosterone level below 300ng / dL) in 2162 men aged 45 years or older presenting to primary care offices was 38.7 % in a study by Mulligan and colleagues.

Dandona P, Rosenberg MT.. A practical guide to male hypogonadism in the primary care setting.

In both males and females, hypogonadism can be primary (diseases of the gonad itself) or secondary to another disorder (e.g., Cushing's syndrome).